Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Treace Medical Concepts (TMCI) Non Operating Investment Income (2022 - 2025)

Treace Medical Concepts (TMCI) has disclosed Non Operating Investment Income for 4 consecutive years, with -$11000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Non Operating Investment Income rose 88.3% year-over-year to -$11000.0, compared with a TTM value of -$25000.0 through Dec 2025, up 62.12%, and an annual FY2025 reading of -$25000.0, up 62.12% over the prior year.
  • Non Operating Investment Income was -$11000.0 for Q4 2025 at Treace Medical Concepts, down from $33000.0 in the prior quarter.
  • Across five years, Non Operating Investment Income topped out at $311000.0 in Q4 2023 and bottomed at -$163000.0 in Q2 2023.
  • Average Non Operating Investment Income over 4 years is $5538.5, with a median of -$27000.0 recorded in 2022.
  • The sharpest move saw Non Operating Investment Income skyrocketed 1251.85% in 2023, then plummeted 224.14% in 2024.
  • Year by year, Non Operating Investment Income stood at -$27000.0 in 2022, then surged by 1251.85% to $311000.0 in 2023, then tumbled by 130.23% to -$94000.0 in 2024, then skyrocketed by 88.3% to -$11000.0 in 2025.
  • Business Quant data shows Non Operating Investment Income for TMCI at -$11000.0 in Q4 2025, $33000.0 in Q3 2025, and -$7000.0 in Q2 2025.